{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"068-549-451-152-544","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"068-549-451-152-544","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8892,"type":"PATENT","title":"University of Wisconsin Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15082,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8214,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners = \"Wisconsin University\" , \"University of Wisconsin\", \"Wisconsin Univ\", \" Univ Wisconsin\" , \"Wisco* Alum* Res* Found*\".
Select more for logical variants
Add to collection
Search Applicants and Owners = \"Wisconsin University\" , \"University of Wisconsin\", \"Wisconsin Univ\", \" Univ Wisconsin\" , \"Wisco* Alum* Res* Found*\".
Select more for logical variants
Add to collection
a) providing a subject and an effective amount of at least one non-corneotoxic ophthalmic preparation that affects actin filament integrity in the eye of said subject; and
b) administering to said subject, said preparation, whereby the aqueous humor outflow of said subject is enhanced."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1 , wherein said non-comeotoxic ophthalmic preparation comprises at least one macrolide or a pharmaceutically acceptable salt thereof."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2 , wherein said macrolide is selected from the group consisting of latrunculin-A, latrunculin-B, swinholide-A, and jasplakinolide."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1 , wherein said subject has glaucoma."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1 , wherein said administration is topical."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1 , wherein said administration is intracameral."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1 , wherein said administration is intracanalicular."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A method of enhancing aqueous humor outflow in the eye, comprising:
a) providing a subject having glaucoma, and an ophthalmic preparation comprising an effective amount of at least one macrolide or a pharmaceutically acceptable salt thereof; and
b) administering said ophthalmic preparation to said subject thereby enhancing aqueous humor outflow in the eye of said subject."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8 , wherein said ophthalmic preparation affects actin filament integrity in the eye of said subject."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8 , wherein said macrolide is selected from the group consisting of latrunculin-A, latrunculin-B, swinholide-A, and jasplakinolide."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8 , wherein said administration is topical."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8 , wherein said administration is intracameral."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 8 , wherein said administration is intracanalicular."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["A method of preventing the progression of glaucoma, comprising the steps of:
a) providing a subject having glaucoma and a non-comeotoxic ophthalmic preparation that affects actin filament integrity in the eye; and
b) administering said non-comeotoxic ophthalmic preparation to said subject under conditions such that the progression of said glaucoma is prevented."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14 , wherein said non-corneotoxic ophthalmic preparation comprises at least one macrolide."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15 , wherein said macrolide is selected from the group consisting of latrunculin-A, latrunculin-B, swinholide-A, and jasplakinolide."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14 , wherein said administration is topical."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14 , wherein said administration is intracameral."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14 , wherein said administration is intracanalicular."],"number":19,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}